JWH-019

JWH-019 is a synthetic cannabinoid from the naphthoylindole family. It acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a binding affinity of 9.00nM at CB1 and 2.94nM at CB2.

Chemistry

JWH-019 is part of the naphthoylindole family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids including JWH-018, JWH-073, and JWH-200. The compound is named after the initials of its developer, John W. Huffman, a chemist at Clemson University.

Pharmacology

JWH-019 acts as a full agonist at the CB1 and CB2 cannabinoid receptors. The CB1 receptor is found primarily in the brain, and is responsible for the psychoactive effects of cannabinoids. The CB2 receptor is found primarily in the immune system, and is thought to modulate the body's response to pain and inflammation.

Effects

The effects of JWH-019 are similar to those of other synthetic cannabinoids and include relaxation, euphoria, altered perception, and in some cases, hallucinations. However, the compound is also associated with a number of adverse effects including anxiety, paranoia, and in rare cases, seizures.

Legal Status

The legal status of JWH-019 varies by country. In the United States, it is a Schedule I controlled substance, making it illegal to manufacture, distribute, or possess without a license. In the United Kingdom, it is a Class B drug under the Misuse of Drugs Act.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia